Signals transduced by Eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers

被引:13
作者
Lau, Andreas [1 ]
Le, Nghia [1 ]
Nguyen, Claudia [1 ]
Kandpal, Raj P. [1 ]
机构
[1] Western Univ Hlth Sci, Dept Basic Med Sci, Pomona, CA 91766 USA
关键词
Eph receptors; Ephrin ligands; Receptor tyrosine kinases; Human cancers; Breast cancer; Lung cancer; Brain cancer; Prostate cancer; Colorectal cancer; MAPK pathway; mTOR pathway; FOCAL-ADHESION-KINASE; BREAST-CARCINOMA CELLS; CENTRAL-NERVOUS-SYSTEM; N-CADHERIN EXPRESSION; TYROSINE KINASE; LUNG-CANCER; ERK PHOSPHORYLATION; CONTACT INHIBITION; PROSTATE CARCINOMA; CYCLE PROGRESSION;
D O I
10.1016/j.cellsig.2022.110579
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Eph receptors, the largest known family of receptor tyrosine kinases, and ephrin ligands have been implicated in a variety of human cancers. The novel bidirectional signaling events initiated by binding of Eph receptors to their cognate ephrin ligands modulate many cellular processes such as proliferation, metastasis, angiogenesis, inva-sion, and apoptosis. The relationships between the abundance of a unique subset of Eph receptors and ephrin ligands with associated cellular processes indicate a key role of these molecules in tumorigenesis. The combi-natorial expression of these molecules converges on MAP kinase and/or AKT/mTOR signaling pathways. The intracellular target proteins of the initial signal may, however, vary in some cancers. Furthermore, we have also described the commonality of up-and down-regulation of individual receptors and ligands in various cancers. The current state of research in Eph receptors illustrates MAP kinase and mTOR pathways as plausible targets for therapeutic interventions in various cancers.
引用
收藏
页数:12
相关论文
共 161 条
[11]  
Bhushan L, 2014, CANCER GENOM PROTEOM, V11, P239
[12]   EphB6 Receptor Modulates Micro RNA Profile of Breast Carcinoma Cells [J].
Bhushan, Lokesh ;
Kandpal, Raj P. .
PLOS ONE, 2011, 6 (07)
[13]   Oncogenic Effects of High MAPK Activity in Colorectal Cancer Mark Progenitor Cells and Persist Irrespective of RAS Mutations [J].
Blaj, Cristina ;
Schmidt, Eva Marina ;
Lamprecht, Sebastian ;
Hermeking, Heiko ;
Jung, Andreas ;
Kirchner, Thomas ;
Horst, David .
CANCER RESEARCH, 2017, 77 (07) :1763-1774
[14]   EphA2 in the Early Pathogenesis and Progression of Non-Small Cell Lung Cancer [J].
Brannan, Jennifer M. ;
Sen, Banibrata ;
Saigal, Babita ;
Prudkin, Ludmila ;
Behrens, Carmen ;
Solis, Luisa ;
Dong, Wenli ;
Bekele, B. Nebiyou ;
Wistuba, Ignacio ;
Johnson, Faye M. .
CANCER PREVENTION RESEARCH, 2009, 2 (12) :1039-1049
[15]   The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling [J].
Brantley-Sieders, Dana M. ;
Zhuang, Guanglei ;
Hicks, Donna ;
Bin Fang, Wei ;
Hwang, Yoonha ;
Cates, Justin M. M. ;
Coffman, Karen ;
Jackson, Dowdy ;
Bruckheirner, Elizabeth ;
Muraoka-Cook, Rebecca S. ;
Chen, Jin .
JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :64-78
[16]   Eph/Ephrin Profiling in Human Breast Cancer Reveals Significant Associations between Expression Level and Clinical Outcome [J].
Brantley-Sieders, Dana M. ;
Jiang, Aixiang ;
Sarma, Krishna ;
Badu-Nkansah, Akosua ;
Walter, Debra L. ;
Shyr, Yu ;
Chen, Jin .
PLOS ONE, 2011, 6 (09)
[17]   EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation [J].
Brantley-Sieders, DM ;
Caughron, J ;
Hicks, D ;
Pozzi, A ;
Ruiz, JC ;
Chen, J .
JOURNAL OF CELL SCIENCE, 2004, 117 (10) :2037-2049
[18]   Homeobox A9 transcriptionally regulates the EphB4 receptor to modulate endothelial cell migration and tube formation [J].
Bruhl, T ;
Urbich, C ;
Aicher, D ;
Acker-Palmer, A ;
Zeiher, AM ;
Dimmeler, S .
CIRCULATION RESEARCH, 2004, 94 (06) :743-751
[19]   The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment [J].
Buckens, Oscar J. ;
El Hassouni, Btissame ;
Giovannetti, Elisa ;
Peters, Godefridus J. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (06) :567-581
[20]  
Cheng N, 2002, MOL CANCER RES, V1, P2